Jennifer Malin, MD, staff vice president, Clinical Strategy, Anthem, spoke about her health plan’s requirements on quality measures and whether they resonate what CMS requires providers to submit.
Jennifer Malin, MD, staff vice president, Clinical Strategy, Anthem, spoke about her health plan’s requirements on quality measures and whether they resonate what CMS requires providers to submit.
“What we have been focusing on and reports that we’re going to be providing to practices include adherence to our pathways as well as [emergency department] utilization and hospitalizations during treatment and access to hospice and other end-of-life care,” Dr Malin said. She added that these measures are a part of what CMS requires through the Oncology Care Model.
However, for Dr Malin, she sees challenges with developing a small set of more meaningful measures that can be used across their entire network. The crux is to derive maximum information without placing further burden on the practices. She said that Anthem has been working to find a “sweet spot of measures” to help practices compare themselves with other practices across the health plan’s network.
Dr Malin said that America’s Health Insurance Plans, or AHIP, has a work group that has brought together private payers and CMS, which “led to the short list of measures that's included in the current oncology care model.” The challenge, however, remains the lack of standardization across practices, with respect to the data systems used. She went on to add that with pay-for-performance and accountability, the National Quality Forum would ultimately ensure that a said measure is up to par—so that’s the least of her concerns.
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More